[New analgesics coming. Monoclonal NGF antibody takes the lead].
Claesson
Alf
A
Department of Medicinal Chemistry, AstraZeneca R&D, Södertälje. alf.claesson@astrazeneca.com
D000700:Analgesics / Q000008:administration & dosage / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology; D055808:Drug Discovery; D006801:Humans; D020932:Nerve Growth Factor / Q000276:immunology; D010146:Pain / Q000188:drug therapy*; D020917:Receptor, trkA / Q000187:drug effects; D015222:Sodium Channels / Q000187:drug effects; D050916:TRPV Cation Channels / Q000037:antagonists & inhibitors
D000700:Analgesics; D000911:Antibodies, Monoclonal; D015222:Sodium Channels; D050916:TRPV Cation Channels; D020932:Nerve Growth Factor; D020917:Receptor, trkA